1.62
Schlusskurs vom Vortag:
$1.45
Offen:
$1.46
24-Stunden-Volumen:
11.61M
Relative Volume:
1.30
Marktkapitalisierung:
$486.14M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-1.08
EPS:
-1.5
Netto-Cashflow:
$-260.90M
1W Leistung:
+12.50%
1M Leistung:
+27.56%
6M Leistung:
-10.50%
1J Leistung:
-10.00%
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Vergleichen Sie PACB mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PACB
Pacific Biosciences Of California Inc
|
1.62 | 432.12M | 188.87M | -400.38M | -260.90M | -1.50 |
![]()
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-11 | Herabstufung | UBS | Buy → Neutral |
2024-06-03 | Fortgesetzt | Jefferies | Buy |
2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
2023-12-14 | Eingeleitet | Guggenheim | Neutral |
2023-12-14 | Eingeleitet | Stephens | Overweight |
2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
2023-11-17 | Hochstufung | UBS | Neutral → Buy |
2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2023-09-28 | Eingeleitet | Bernstein | Outperform |
2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
2023-06-30 | Eingeleitet | Goldman | Buy |
2023-05-10 | Eingeleitet | Barclays | Equal Weight |
2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
2023-02-02 | Eingeleitet | UBS | Neutral |
2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
2021-10-15 | Fortgesetzt | Cowen | Market Perform |
2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
2018-10-19 | Eingeleitet | Cowen | Outperform |
2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
2017-09-28 | Herabstufung | CL King | Buy → Neutral |
2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
2016-06-27 | Eingeleitet | CL King | Buy |
2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
2015-02-04 | Bestätigt | Maxim Group | Buy |
2013-09-26 | Bestätigt | Maxim Group | Buy |
2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Is Pacific Biosciences of California Inc. a good long term investmentPhenomenal wealth increase - Autocar Professional
What analysts say about Pacific Biosciences of California Inc. stockFree Market Volatility Navigation Tips - jammulinksnews.com
What drives Pacific Biosciences of California Inc. stock priceRapid capital growth - jammulinksnews.com
QIAGEN launches long-read sequencing panels for complex genomic regions By Investing.com - Investing.com Canada
PACB Stock Rally: Bullish Signs or Temporary Spike? - StocksToTrade
Pacific Biosciences of California Inc. Stock Analysis and ForecastOutstanding capital returns - jammulinksnews.com
PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025 - Yahoo Finance
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
How long-read sequencing uncovers hitchhikers of the genomic galaxy in parasitic fungi - PacBio
Pacific Biosciences Stock Jumps Amid Strategic Acquisitions - StocksToTrade
Pacific Biosciences Sees Stock Uptick Following Strategic Moves - timothysykes.com
Chromosome-level genome assembly with telomeric repeats at scaffold ends for Rhabdosargus sarba - Nature
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
Further Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Could Introduce Price Risks After 29% Bounce - simplywall.st
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Pacific Biosciences (PACB) Upgraded to Strong Buy: Here's What You Should Know - MSN
PACB Stock Price and Chart — NASDAQ:PACB - TradingView
Pacific Biosciences Sees Stock Surge After Latest Product Launch - timothysykes.com
Pacific Biosciences Targets Profitability by 2027 With Record Consumables Revenue - Insider Monkey
Why PACB’s Stock is Rising? - StocksToTrade
How the Long Read Sequencing Market Will Evolve by 2032Growth, - openPR.com
The 5 Most Interesting Analyst Questions From PacBio’s Q1 Earnings Call - Yahoo Finance
Barclays Adjusts Price Target for PacBio (PACB) Amid Funding Con - GuruFocus
Third Generation Sequencing Market Set to Witness Significant - openPR.com
Long Read Sequencing Market Projected to Reach USD 6.98 - GlobeNewswire
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Following a 41% decline over last year, recent gains may please Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional owners - simplywall.st
Celebrating Father’s Day with new discoveries of the Y chromosome achieved with HiFi sequencing - PacBio
Transcript : Pacific Biosciences of California, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
PACB Q1 Earnings Call: Cost Reductions and Clinical Adoption Offset Market Headwinds - Yahoo Finance
Pacific Biosciences Approves Key Proposals at Annual Meeting - TipRanks
Powered by PacBio: Selected publications from May 2025 - PacBio
Pacific Biosciences Of California To Present At Jefferies Conference; Webcast At 8:45 AM ET - Nasdaq
Amgen To Present At Jefferies Healthcare Conference; Webcast At 9:20 AM ET - Nasdaq
Q1 Earnings Roundup: PacBio (NASDAQ:PACB) And The Rest Of The Life Sciences Tools & Services Segment - Yahoo Finance
Pacific Biosciences of California, Target ALS Collaborate for Genomic Study - marketscreener.com
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):